A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes

INTRODUCTION: To investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of tirzepatide in Chinese patients with type 2 diabetes (T2D). METHODS: In this phase 1, double-blind, placebo-controlled, multiple dose study, patients were randomized into one of two cohorts to receive once-weekly subcutaneous tirzepatide or placebo. The initial tirzepatide dose in both cohorts was 2.5 mg, which was increased by 2.5 mg every 4 weeks to a maximum final dose of 10.0 mg at week 16 (Cohort 1) or 15.0 mg at week 24 (Cohort 2). The primary outcome was the safety and tolerability of tirzepatide. RESULTS: Twenty-four patients were randomized (tirzepatide 2.5–10.0 mg: n = 10, tirzepatide 2.5–15.0 mg: n = 10, placebo: n = 4); 22 completed the study. The most frequently reported treatment-emergent adverse events (TEAEs) among patients receiving tirzepatide were diarrhea and decreased appetite; most TEAEs were mild and resolved spontaneously with no serious adverse events reported in the tirzepatide groups and one in the placebo group. The plasma concentration half-life of tirzepatide was approximately 5–6 days. Mean glycated hemoglobin (HbA1c) decreased over time from baseline in the 2.5–10.0 mg (− 2.4%) and 2.5–15.0 mg (− 1.6%) tirzepatide groups, at week 16 and week 24, respectively, but remained steady in patients receiving placebo. Body weight decreased from baseline by − 4.2 kg at week 16 in the tirzepatide 2.5–10.0 mg group and by − 6.7 kg at week 24 in the 2.5–15.0 mg group. Mean fasting plasma glucose levels fell from baseline by − 4.6 mmol/L in the tirzepatide 2.5–10.0 mg group at week 16 and by − 3.7 mmol/L at week 24 in the tirzepatide 2.5–15.0 mg group. CONCLUSIONS: Tirzepatide was well tolerated in this population of Chinese patients with T2D. The safety, tolerability, PK, and PD profile of tirzepatide support once-weekly dosing in this population. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT04235959. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02536-8.